I. VEGF165: The Master Regulator of Angiogenesis
VEGF165 is the primary isoform of vascular endothelial growth factor, playing an irreplaceable central role in the process of blood vessel formation.
Molecular Characteristics and Structural Features:
Gene Encoding: Produced by the VEGF-A gene through alternative splicing
Protein Structure: Retains all receptor-binding domains and possesses heparin-binding capability
Isoform Advantage: Achieves optimal balance between diffusibility and matrix-binding properties
Biological Functions and Mechanisms:
Promotes Angiogenesis: Directly stimulates endothelial cell proliferation, migration, and lumen formation
Enhances Vascular Permeability: Facilitates plasma protein extravasation, providing a matrix for angiogenesis
Stem Cell Recruitment: Mobilizes bone marrow-derived endothelial progenitor cells to participate in vascular construction
Signaling Pathways: Primarily activates downstream MAPK and PI3K/Akt pathways through binding with VEGFR2
II. The Deep Association Between VEGF165 and Diseases
1. Tumor Development and Progression
VEGF165 plays a critical role in tumor biology:
Tumor Angiogenesis
Mediates the activation of the tumor "angiogenic switch"
Promotes the formation of abnormal tumor vascular networks
Supplies nutrients essential for tumor growth
Metastasis and Invasion
Increases vascular permeability, facilitating tumor cell extravasation
Shapes the pre-metastatic microenvironment
Enhances tumor invasiveness
Clinical Significance: Detection of VEGF165 expression levels has become a prognostic indicator for various tumors, with high levels typically predicting poor outcomes.
2. Ophthalmic Diseases
Age-Related Macular Degeneration
Drives choroidal neovascularization
Increases vascular permeability, leading to retinal edema
Promotes fibrovascular membrane formation
Diabetic Retinopathy
Mediates pathological retinal neovascularization
Disrupts the blood-retinal barrier
Promotes vitreous hemorrhage and retinal detachment
Therapeutic Breakthrough: Anti-VEGF165 drugs (e.g., ranibizumab, aflibercept) have become first-line treatments for ophthalmic diseases.
3. Cardiovascular Diseases
Coronary Artery Disease
Participates in the establishment of coronary collateral circulation
Affects myocardial perfusion and functional recovery
Closely related to ischemic preconditioning
Peripheral Artery Disease
Regulates angiogenesis in ischemic tissues
Influences lower limb blood flow perfusion
Determines tissue survival and ulcer healing
4. Other Major Diseases
Rheumatoid Arthritis
Promotes synovial pannus formation
Exacerbates joint inflammation and destruction
Affects disease activity
Neurological Diseases
Participates in blood-brain barrier function regulation
Affects neurovascular unit integrity
Exerts protective effects in cerebral ischemia
III. Targeted Therapies and Clinical Prospects
1. Current Therapeutic Strategies
Monoclonal Antibodies
Bevacizumab: The first approved VEGF-targeting drug
Ranibizumab: Specialized formulation for ophthalmic diseases
Fully Humanized Antibodies: Reduce immunogenicity
Receptor Fusion Proteins
Aflibercept: High-affinity VEGF trap
Conbercept: Multi-target fusion protein
Small Molecule Inhibitors
Multi-target TKIs such as sunitinib and sorafenib
Specific VEGFR2 inhibitors
2. Advances in Personalized Therapy
Biomarker Guidance
VEGF165 expression level detection
Genetic polymorphism analysis
Treatment response prediction models
Combination Therapy Strategies
Combination with immune checkpoint inhibitors
Synergistic use with chemotherapeutic agents
Radiosensitizing effects
3. Challenges and Solutions
Resistance Mechanisms
Activation of compensatory angiogenic pathways
Adaptive changes in the tumor microenvironment
Optimal timing for vascular normalization
Safety Optimization
Management of adverse effects such as hypertension and proteinuria
Control of arterial thrombotic event risks
Personalized dose adjustment strategies
IV. Future Research Directions
Frontiers in Basic Research
Functional analysis of VEGF165 isoform specificity
New discoveries in non-angiogenic functions
Exploration of epigenetic regulatory mechanisms
Translational Medicine Focus
Development of novel drug delivery systems
Tissue-specific targeting strategies
Solutions to overcome resistance mechanisms
Clinical Research Priorities
Exploration of optimal treatment timing
Optimization of combination regimens
Long-term safety assessments
Conclusion
As a central node in the angiogenesis regulatory network, VEGF165 research not only deepens our understanding of physiological blood vessel formation but also provides a critical therapeutic target for numerous major diseases. From basic biology to clinical translation, VEGF165 research remains at the forefront of vascular biology and precision medicine.
In the field of VEGF165-related research, high-quality recombinant proteins and reliable research tools are key to advancing scientific progress. UA Bio, leveraging advanced protein engineering technology platforms, offers a series of high-quality UA Protein products, including VEGF165 protein. Our products undergo rigorous quality validation to ensure biological activity and batch consistency, providing robust technical support for global researchers in vascular biology, drug development, and disease mechanism studies.
With deepening insights into the VEGF165 signaling network and continuous innovation in novel targeting strategies, we have every reason to believe that research on this pivotal molecule will continue to yield breakthroughs in human disease treatment, ushering in a new era of anti-angiogenic therapy. In the future, precision modulation strategies based on VEGF165 will undoubtedly bring hope to more patients.
